Scientists Use 3-D Printer to Speed Human Embryonic Stem Cell Research
By Larry Greenemeier,
Scientific American
| 02. 04. 2013
Every week, it seems, there’s a new breakthrough in 3-D printing that promises us the ability to (eventually) fabricate some new thing in one of those glass-walled wonder boxes. Such things have included everything from
spare parts for the International Space Station above to the
beef on our dinner plates to the
organs inside our bodies. Although this last idea of fabricating body parts may seem the most fanciful, a team of scientists is reporting a breakthrough in 3-D printing using human embryonic stem cells that could purportedly lead to life-like bioengineered tissue and, eventually, artificial organs tailor-made for specific patients.
Researchers have been able to engineer tissue samples in the past by combining artificial scaffold-like structures and animal cells. Depositing human embryonic stem cells in cultures using a 3-D printer offers some advantages. In particular, the cells can be positioned in droplets of uniform size cheaper, faster and more easily than using manual methods. This uniformity is important for researchers trying to generate specific cell types.
Whereas human embryonic stem cells have proved too fragile to print in...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...